Stoke Therapeutics Inc.’s speeded-up timeline for zorevunersen, the antisense oligonucleotide in development with Biogen Inc.

Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or... Copyright ©2026. All Rights Reserved.

The U.S. FDA has cleared Tessera Therapeutics Inc.’s IND application for TSRA-196, its lead in vivo gene editing therapy for α-1 antitrypsin deficiency (AATD). The Australian Human Research Ethics ...

Both rare and common genetic variants contribute to the risk of schizophrenia and CALN1 has been proposed as a candidate schizophrenia risk gene.

Adenosine deaminase acting on RNA (ADAR) is the enzyme responsible for adenosine-to-inosine (A-to-I) RNA editing, a process ...

Keiferx LLC has entered into a research collaboration and option agreement with Amneal Pharmaceuticals Inc. to support the pre-IND development of KFRX-06, Keiferx’s brain-penetrant preclinical ...

Fannin Partners LLC has been awarded a $300,000 phase I Small Business Innovation Research (SBIR) grant from the National Eye ...

Cellbxhealth plc, previously called Angle plc, appointed CEO Peter Collins along with several non-executives to its board as ...

Monash University has identified cyclic peptides acting as melanocortin MC5 receptor (MC5R) agonists reported to be useful for the treatment of diabetes, obesity, cardiomyopathy, heart failure, renal ...

After raising AU$29 million (US$19.44 million) in a series A round, Rage Biotech Pty Ltd. is beginning phase I trials of its ...

Enodia Therapeutics SAS has raised €20.7 million ($25 million) in seed financing to advance its work developing novel small-molecule therapies for targeted protein degradation at the point of ...

Hanmi Pharmaceutical Co. Ltd. has disclosed polypeptides acting as triple agonists of glucagon like peptide 1 receptor (GLP-1R), glucagon receptor (GCGR) and glucose-dependent insulinotropic receptor ...